The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-19. Anything still debated is marked as such rather than presented as settled.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
In Panjshir, residents reported hearing a loud explosion, and said that the Bazarak area was shaken by a strong tremor. In Herat, residents stated that fighter jets were patrolling over the city's airport and that gunfire was heard from the airport. In Badakhshan, residents reported that an airstrike had taken place in Fayzabad. Taliban officials did not release any official details regarding these airstrikes. A PAF airstrike was also reported in Afghanistan's Nuristan province. On the same day, a spokesperson for the Taliban-led Afghan government stated that, in the past 24 hours Taliban forces had attacked Pakistan's border outposts along the provinces of Kandahar, Nangarhar, Kunar, Nuristan, Khost, Paktika and Paktika. According to the spokesperson, since the start of the hostilities, Taliban forces had killed more than 150 Pakistan's troops, injured 200 others, and destroyed 40 border outposts belonging to Pakistan. Afghan MoD claimed that three Pakistani personnel were killed and one was captured in an attack on Pakistani forces in Spin Boldak. The spokesperson also stated that 28 Taliban fighters had been killed in the clashes, while 42 others had been wounded. As per the spokesperson, 110 Afghan civilians had been killed, while 120 others had been wounded. The spokesperson added that Pakistani attacks in Afghanistan have damaged public facilities, mosques, and houses. The spokesperson also said that Afghanistan has approached Russia, China, the European Union, and United Kingdom to help end the war.
=== Reducing gastric reflux === The stomach produces gastric juice, a mixture consisting of gastric acid (mainly hydrochloric acid), lipase, and pepsin to enable food digestion. Constriction of the lower esophageal sphincter protects the esophageal mucosa by preventing reflux, the backflow of acid and gastric contents into the esophagus. The acute angle of His and the lower crura of the diaphragm also help this sphincteric action.
== Biological activity == Concanavalin A interacts with diverse receptors containing mannose carbohydrates, notably rhodopsin, blood group markers, insulin receptors, the immunoglobulins and the carcino-embryonary antigen (CEA). It also interacts with lipoproteins. ConA strongly agglutinates erythrocytes irrespective of blood-group, and various cancerous cells. It was demonstrated that transformed cells and trypsin-treated normal cells do not agglutinate at 4 °C, thereby suggesting that there is a temperature-sensitive step involved in ConA-mediated agglutination. ConA-mediated agglutination of other cell types has been reported, including muscle cells, B-lymphocytes (through surface immunoglobulins), fibroblasts, rat thymocytes, human fetal (but not adult) intestinal epithelial cells, and adipocytes. ConA is a lymphocyte mitogen. Similar to phytohemagglutinin (PHA), it is a selective T cell mitogen relative to its effects on B cells. PHA and ConA bind and cross-link components of the T cell receptor, and their ability to activate T cells is dependent on expression of the T cell receptor. ConA interacts with the surface mannose residues of many microbes, including the bacteria E. coli, and Bacillus subtilis and the protist Dictyostelium discoideum. It has also been shown as a stimulator of several matrix metalloproteinases (MMPs). ConA has proven useful in applications requiring solid-phase immobilization of glycoenzymes, especially those that have proved difficult to immobilize by traditional covalent coupling.
Sources: en.wikipedia.org
Mercenaries and multinational corporations such as Chiquita Brands International are some of the international actors that have contributed to the violence of the conflict. Beginning in the mid-1970s Colombian drug cartels became major producers, processors and exporters of illegal drugs, primarily marijuana and cocaine. On 4 July 1991, a new Constitution was promulgated. The changes generated by the new constitution are viewed as positive by Colombian society.
This earlier study also found that dihydroxyacetone also has an effect on the amino acids and nucleic acids which is bad for the skin. The free radicals are due to the action of UV light on AGE (advanced glycation end-products) as a result of the reaction of DHA with the skin, and the intermediates, such as Amadori products (a type of AGE), that lead to them. AGEs are behind the damage to the skin that occurs with high blood sugar in diabetes where similar glycation occurs. AGEs absorb and provide a little protection against some of the damaging factors of UV (up to SPF 3), However, they do not have melanin's extended electronic structure that dissipates the energy, so part of it goes towards starting free radical chain reactions instead, in which other AGEs participate readily. Overall tanner enhances free radical injury. Although some self-tanners contain sunscreen, its effect will not last as long as the tan. The stated SPF is only applicable for a few hours after application. Despite darkening of the skin, an individual is still susceptible to UV rays, therefore an overall sun protection is still very necessary. There may also be some inhibition of vitamin D production in DHA-treated skin. The color effect is temporary and fades gradually over 3 to 10 days. Some of these products also use erythrulose which works identically to DHA, but develops more slowly. Both DHA and erythrulose have been known to cause contact dermatitis.
Menin is a protein that in humans is encoded by the MEN1 gene. Menin is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome) and has autosomal dominant inheritance. Variations in the MEN1 gene can cause pituitary adenomas, hyperparathyroidism, pancreatic neuroendocrine tumors, gastrinoma, and adrenocortical cancers. In vitro studies have shown that menin is localized to the nucleus, possesses two functional nuclear localization signals, and inhibits transcriptional activation by JunD. However, the function of this protein is not known. Two messages have been detected on northern blots but the larger message has not been characterized. Two variants of the shorter transcript have been identified where alternative splicing affects the coding sequence. Five variants where alternative splicing takes place in the 5' UTR have also been identified.
Sources: en.wikipedia.org
=== Current and resistance === The resistance of the filament is temperature dependent. The cold resistance of tungsten-filament lamps is about 1⁄15 the resistance when operating. For example, a 100-watt, 120-volt lamp has a resistance of 144 ohms when lit, but the cold resistance is much lower (about 9.5 ohms). Since incandescent lamps are resistive loads, simple phase-control TRIAC dimmers can be used to control brightness. Electrical contacts may carry a "T" rating symbol indicating that they are designed to control circuits with the high inrush current characteristic of tungsten lamps. For a 100-watt, 120-volt general-service lamp, the current stabilizes in about 0.10 seconds, and the lamp reaches 90% of its full brightness after about 0.13 seconds.
In normal conditions, the human intestine absorbs mainly nonphosphorylated B6 vitamers. The phosphorylated forms of B6 and the glucoside of pyridoxine can be hydrolyzed by intestinal phosphatases and an intestinal glycosidase, respectively, to promote passive diffusion of pyridoxamine, pyridoxine and pyridoxal. In the liver or intestine, they are then rephosphorylated by pyridoxal kinase (EC 2.7.1.35) to avoid inverse diffusion A transport protein / membrane carrier of PLP (and other phosphorylated forms of B6) is the human membrane enzyme NAPE-PLD N-acyl phosphatidylethanolamine-specific phospholipase D of the endocannabinoid system. In the presence of bile acids (e.g., digestion), NAPE-PLD with its internal channel creates membrane-pores as dynamic conductive pathways through which the charged cofactors of vitamin B6 can diffuse through cell membranes and membranes of subcellular compartments (e.g., mitochondria, peroxisome, and endosome), where they exert the specific enzymatic activities. NAPE-PLD is thus functional to the intracellular uptake and mobilization of PLP, and to the increased demand of the cofactor in pathological conditions having a higher endocannabinoid tone. Intracellular-free PLP concentrations are maintained at approximately 1 μM to prevent inappropriate reactions. Proteins that bind PLP and help maintain low-free PLP concentrations include glycogen phosphorylase in muscle, hemoglobin in erythrocytes, albumin in plasma, and NAPE-PLD mainly in the brain, gut, liver, kidney and reproductive system.
== Pharmacology == Itopride acts as a selective dual D2 receptor antagonist and acetylcholinesterase inhibitor. There is evidence that itopride may have prokinetic effects throughout the gastrointestinal tract from the stomach to the end of the colon. The pharmacokinetics of itopride appear to differ between Asian and Caucasian populations, with Caucasians having 30-50 percent lower blood levels of itopride after oral administration. Itopride poorly penetrates across the blood brain barrier because of its high polarity and thus itopride does not tend to cause any central nervous system adverse effects. Itopride has no effect on potassium channels. Similarly to other D2 receptor antagonists, itopride has been found to dose-dependently increase prolactin levels.
== Principle == In the case of M13 filamentous phage display, the DNA encoding the protein of interest is inserted into the gene encoding either the minor (pIII) or the major (pVIII) coat protein. The modified coat protein gene and the rest of the phage genome is then introduced into E. coli bacteria, which produce phage virions with the relevant protein fragment as part of their outer coat phage and the DNA encoding for these proteins packaged inside the phage. The phages can then be selected using e.g. DNA or protein molecules immobilized on the surface of a microplate. Specifically, phages that display proteins that binds to those targets will remain attached, while others will be removed by washing. Those that remain can be eluted and amplified by bacterial infection. The repeated cycling of selection, elution and amplification is sometimes referred to as 'panning', in reference to the enrichment of a sample of gold by removing undesirable materials. Phage eluted in the final step can be sequenced to identify the selected proteins. During amplification step, additional mutations may be introduced into the genes encoding the proteins of interest, enabling a directed evolution protocol. Elution can be done combining low-pH elution buffer with sonification, which, in addition to loosening the peptide-target interaction, also serves to detach the target molecule from the immobilization surface. This ultrasound-based method enables single-step selection of a high-affinity peptide.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。